[Differentiated thyroid carcinoma: initial evaluation and follow-up].
Thyroid carcinoma accounts for roughly 1% of all new malignant diseases. Of these, at least 94% are differentiated thyroid carcinoma (DTC), either papillary thyroid carcinoma or follicular thyroid carcinoma. Patients with DTC are usually considered as having a good prognosis, 80% of patients are cured, 20% will develop loco-regional recurrence and 5-10% distant metastasis. However, the disease may have an aggressive course in some patients. The identification of these patients has a major impact in the clinical management of DTC. Several prognostic factors and classification will be addressed, as well the most useful tests for patients follow-up.
Golbert
Lenara
L
Serviço de Endocrinologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS.
Wajner
Simone Magagnin
SM
Rocha
Andreia Possatti da
AP
Maia
Ana Luiza
AL
Gross
Jorge Luiz
JL
D018263:Adenocarcinoma, Follicular / Q000175:diagnosis / Q000556:secondary / Q000628:therapy; D002291:Carcinoma, Papillary / Q000175:diagnosis / Q000556:secondary / Q000628:therapy; D005500:Follow-Up Studies; D006801:Humans; D009361:Neoplasm Invasiveness; D009363:Neoplasm Proteins / Q000097:blood; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis; D009367:Neoplasm Staging; D011379:Prognosis; D013954:Thyroglobulin / Q000097:blood; D013964:Thyroid Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy
D009363:Neoplasm Proteins; D013954:Thyroglobulin